Woodline Partners LP has boosted its investment in CG Oncology (NASDAQ:CGON) by 21.5% during the first quarter. After purchasing an additional 135,472 shares, the firm now holds 764,357 shares worth $18,719,000, signaling a notable show of confidence in the biotech company’s future.

CG Oncology, a small biotech firm rivaling Johnson & Johnson, saw its stock soar 44% following promising clinical trial results for its bladder cancer drug. The breakthrough has drawn significant investor attention and could signal a shift in cancer treatment options.